PTSD and payers in psychedelic healthcare
Veteran affairs receive bipartisan support across North America, with public opinion prompting lawmakers and regulators to support innovations in veteran healthcare.
The FDA designated MAPS’ MDMA-assisted therapy for post-traumatic stress disorder (PTSD) a breakthrough therapy in 2017 with regulatory approval expected in 2024.
Earlier this month, Apex Labs received approval for its Phase IIb trial with psilocybin in the treatment of PTSD – with patients taking the psychedelic medicine at home with minimal psychiatric intervention.
This is the first study of its kind in North America and, if successful, could transform how psychedelic medicines are delivered. PSYCH spoke with the company’s CEO Tyler Powell on the announcement.READ MORE